Home > > > > Report Detail

Europe Cancer Biomarker Market Forecast 2019-2027

Publisher Name :
Date: 14-Jan-2019
No. of pages: 75

KEY FINDINGS

The Europe cancer biomarker market is poised to grow at a CAGR of 10.83% for the years 2019-2027. Technological progress in research and developmental activities has progressed the growth of the cancer biomarker market in Europe.

MARKET INSIGHTS

The European market has a huge opportunity to grow in personalized medication on account of the support generated for the biomarkers test, growing medical tourism and the rising number of cancer patients in the region. Also, the various market segments and sub-segments with respect to biomarkers, application, cancer type and profiling technology are proving to be quite profitable for the market growth during the forecast period. However, the lack of acceptance of the cancer biomarker from the general populace, unfavorable compensation and the shortage of skilled personnel are some of the major challenges faced by the market in the region.

COMPETITIVE INSIGHTS

Some of the leading players in the market are Agendia N.V., Becton Dickinson and Company, Qiagen N.V., Diadexus Inc. (Acquired By Diazyme Laboratories), Aureon Biosciences, Inc., Agilent Technologies, Inc., Clarient, Inc. (Acquired By Neogenomics Laboratories), Astellas Pharma Inc., Beckman Coulter, Sanofi, Bristol-Myers Squibb, Abbott Laboratories, Roche Diagnostics Ltd., Illumina, Inc. and Celgene Corporation.

Europe Cancer Biomarker Market Forecast 2019-2027

Table of Contents

1. RESEARCH SCOPE
1.1. STUDY GOALS
1.2. SCOPE OF THE MARKET STUDY
1.3. WHO WILL FIND THIS REPORT USEFUL?
1.4. STUDY AND FORECASTING YEARS
2. RESEARCH METHODOLOGY
2.1. SOURCES OF DATA
2.1.1. SECONDARY DATA
2.1.2. PRIMARY DATA
2.2. TOP DOWN APPROACH
2.3. BOTTOM-UP APPROACH
2.4. DATA TRIANGULATION
3. EXECUTIVE SUMMARY
3.1. MARKET SUMMARY
3.2. KEY FINDINGS
3.2.1. OMIC TECHNOLOGY GENERATED THE HIGHEST REVENUE IN TERMS OF PROFILING TECHNOLOGY
3.2.2. GLYCO BIOMARKERS ARE THE FASTEST GROWING CANCER BIOMARKERS
3.2.3. BREAST CANCER HOLDS THE LARGEST MARKET SHARE IN TERMS OF CANCER TYPE
3.2.4. DIAGNOSTICS APPLICATION IS THE MAJORLY USED CANCER BIOMARKER APPLICATION
4. MARKET DYNAMICS
4.1. MARKET SCOPE & DEFINITION
4.2. MARKET DRIVERS
4.2.1. GROWING PREVALENCE ON RESEARCH OF CANCER BIOMARKERS
4.2.2. ENCOURAGEMENT FOR BIOMARKER DEVELOPMENT BY FDA
4.2.3. IMPROVED PRECISION AND SPEED OF DIAGNOSIS
4.2.4. HIGH INVESTMENT THROUGH GOVERNMENT AND PRIVATE FUNDS IN CANCER RELATED RESEARCH
4.2.5. DEVELOPMENT OF HIGHLY SPECIFIC DRUGS
4.2.6. GROWTH IN IMPORTANCE OF BIOLOGICAL AND TARGETED DRUG THERAPIES
4.2.7. TECHNOLOGICAL ADVANCEMENTS
4.2.8. GROWING PERSONALIZED MEDICINE AND COMPANION DIAGNOSTICS
4.3. MARKET RESTRAINTS
4.3.1. POOR COMPENSATION STRUCTURES
4.3.2. LOW ESTIMATED RATE OF SUCCESSFUL CLINICAL TRIALS OF BIOMARKERS
4.3.3. TECHNICAL ISSUES RELATED TO CANCER BIOMARKERS
4.3.4. HIGH COST OF DRUG DEVELOPMENT
4.3.5. UNCLEAR GOVERNMENT REGULATION AND REIMBURSEMENT POLICIES
4.4. MARKET OPPORTUNITIES
4.4.1. WIDE OPPORTUNITY TO GROW IN PERSONALIZED MEDICATION
4.4.2. SUPPORTS ON BIOMARKERS TEST
4.4.3. GROWING NUMBER OF CANCER PATIENTS AND GROWING MEDICAL TOURISM IN EMERGING ECONOMIES
4.4.4. ADVANCEMENT OF CANCER DRUGS RESEARCH
4.5. MARKET CHALLENGES
4.5.1. LACKING ACCEPTANCE OF THE CANCER BIOMARKER
4.5.2. UNFAVORABLE COMPENSATION SITUATION
4.5.3. HIGH COST OF DEVELOPING COMPANION DIAGNOSTICS
4.5.4. RIGOROUS REGULATORY AGENDA
4.5.5. DEARTH OF SKILFUL WORKERS
5. MARKET BY PROFILING TECHNOLOGY
5.1. OMIC TECHNOLOGY
5.2. IMAGING TECHNOLOGIES
5.3. IMMUNOASSAYS
5.4. CYTOGENETIC-BASED TESTS
6. MARKET BY BIOMARKER
6.1. GENETIC BIOMARKERS
6.2. PROTEIN BIOMARKERS
6.3. GLYCO BIOMARKERS
7. MARKET BY CANCER TYPE
7.1. LUNG CANCER
7.2. BREAST CANCER
7.3. COLORECTAL CANCER
7.4. PROSTATE CANCER
7.5. STOMACH CANCER
7.6. OTHERS CANCER TYPE
8. MARKET BY APPLICATION
8.1. DIAGNOSTICS
8.2. DRUG DISCOVERY AND DEVELOPMENT
8.3. PROGNOSTICS
8.4. RISK ASSESSMENT
8.5. OTHER APPLICATION
9. KEY ANALYTICS
9.1. PORTER'S FIVE FORCE ANALYSIS
9.1.1. THREAT OF NEW ENTRANTS
9.1.2. THREAT OF SUBSTITUTE PRODUCT
9.1.3. BARGAINING POWER OF BUYER
9.1.4. BARGAINING POWER OF SUPPLIERS
9.1.5. INTENSITY OF COMPETITIVE RIVALRY
9.2. KEY BUYING CRITERIA
9.2.1. PRICING
9.2.2. EFFICACY
9.2.3. APPLICATION AND EFFECTIVENESS
9.3. PATENT ANALYSIS
9.4. ONCOLOGY DRUGS APPROVALS BY THE FDA
9.5. OPPORTUNITY MATRIX
10. GEOGRAPHICAL ANALYSIS
10.1. EUROPE
10.1.1. GERMANY
10.1.2. THE UNITED KINGDOM
10.1.3. FRANCE
10.1.4. ITALY
10.1.5. SPAIN
10.1.6. REST OF EUROPE
11. COMPETITIVE LANDSCAPE
11.1. MARKET SHARE ANALYSIS
11.2. COMPANY PROFILES
11.2.1. ABBOTT LABORATORIES
11.2.1.1. COMPANY OVERVIEW
11.2.1.2. PRODUCT PORTFOLIO
11.2.1.3. SCOT ANALYSIS
11.2.1.4. STRATEGIC INITIATIVES
11.2.2. AGENDIA N.V.
11.2.2.1. COMPANY OVERVIEW
11.2.2.2. PRODUCT PORTFOLIO
11.2.2.3. SCOT ANALYSIS
11.2.2.4. STRATEGIC INITIATIVES
11.2.3. AGILENT TECHNOLOGIES, INC.
11.2.3.1. COMPANY OVERVIEW
11.2.3.2. PRODUCT PORTFOLIO
11.2.3.3. SCOT ANALYSIS
11.2.3.4. STRATEGIC INITIATIVES
11.2.4. AUREON BIOSCIENCES, INC
11.2.4.1. COMPANY OVERVIEW
11.2.4.2. PRODUCT PORTFOLIO
11.2.4.3. SCOT ANALYSIS
11.2.4.4. STRATEGIC INITIATIVES
11.2.5. ASTELLAS PHARMA INC.
11.2.5.1. COMPANY OVERVIEW
11.2.5.2. PRODUCT PORTFOLIO
11.2.5.3. SCOT ANALYSIS
11.2.5.4. STRATEGIC INITIATIVES
11.2.6. BECKMAN COULTER
11.2.6.1. COMPANY OVERVIEW
11.2.6.2. PRODUCT PORTFOLIO
11.2.6.3. SCOT ANALYSIS
11.2.6.4. STRATEGIC INITIATIVES
11.2.7. BECTON DICKINSON AND COMPANY
11.2.7.1. COMPANY OVERVIEW
11.2.7.2. PRODUCT PORTFOLIO
11.2.7.3. SCOT ANALYSIS
11.2.7.4. STRATEGIC INITIATIVES
11.2.8. BRISTOL-MYERS SQUIBB
11.2.8.1. COMPANY PROFILES
11.2.8.2. PRODUCT PORTFOLIO
11.2.8.3. SCOT ANALYSIS
11.2.8.4. STRATEGIC INITIATIVES
11.2.9. CELGENE CORPORATION
11.2.9.1. COMPANY OVERVIEW
11.2.9.2. PRODUCT PORTFOLIO
11.2.9.3. SCOT ANALYSIS
11.2.9.4. STRATEGIC INITIATIVES
11.2.10. CLARIENT, INC. (ACQUIRED BY NEOGENOMICS LABORATORIES)
11.2.10.1. COMPANY OVERVIEW
11.2.10.2. PRODUCT PORTFOLIO
11.2.10.3. SCOT ANALYSIS
11.2.10.4. STRATEGIC INITIATIVES
11.2.11. DIADEXUS INC. (ACQUIRED BY DIAZYME LABORATORIES)
11.2.11.1. COMPANY OVERVIEW
11.2.11.2. PRODUCT PORTFOLIO
11.2.11.3. SCOT ANALYSIS
11.2.11.4. STRATEGIC INITIATIVES
11.2.12. ILLUMINA, INC.
11.2.12.1. COMPANY OVERVIEW
11.2.12.2. PRODUCT PORTFOLIO
11.2.12.3. SCOT ANALYSIS
11.2.12.4. STRATEGIC INITIATIVES
11.2.13. ROCHE DIAGNOSTICS LTD
11.2.13.1. COMPANY OVERVIEW
11.2.13.2. PRODUCT PORTFOLIO
11.2.13.3. SCOT ANALYSIS
11.2.13.4. STRATEGIC INITIATIVES
11.2.14. SANOFI
11.2.14.1. COMPANY OVERVIEW
11.2.14.2. PRODUCTS PORTFOLIO
11.2.14.3. SWOT ANALYSIS
11.2.14.4. STRATEGIC INITIATIVES
11.2.15. QIAGEN N.V.
11.2.15.1. COMPANY OVERVIEW
11.2.15.2. PRODUCT PORTFOLIO
11.2.15.3. SCOT ANALYSIS
11.2.15.4. STRATEGIC INITIATIVES


TABLE LIST
TABLE 1 EUROPE CANCER BIOMARKER MARKET 2019-2027 ($ MILLION)
TABLE 2 RECENT RESEARCH ON BIOMARKERS
TABLE 3 LIST OF FDA APPROVED PROTEIN CANCER BIOMARKERS
TABLE 4 POTENTIAL CLINICAL USE OF CANCER BIOMARKERS
TABLE 5 MEDICAL TOURISM PRICES IN US DOLLAR
TABLE 6 EUROPE CANCER BIOMARKER MARKET BY PROFILING TECHNOLOGY 2019-2027 ($ MILLION)
TABLE 7 EUROPE OMIC TECHNOLOGY MARKET 2019-2027 ($ MILLION)
TABLE 8 EUROPE IMAGING TECHNOLOGIES MARKET 2019-2027 ($ MILLION)
TABLE 9 EUROPE IMMUNOASSAYS MARKET 2019-2027 ($ MILLION)
TABLE 10 EUROPE CYTOGENETICS-BASED TESTS MARKET 2019-2027 ($ MILLION)
TABLE 11 EUROPE CANCER BIOMARKER MARKET BY BIOMARKER 2019-2027 ($ MILLION)
TABLE 12 EUROPE GENETIC BIOMARKERS MARKET 2019-2027 ($ MILLION)
TABLE 13 EUROPE PROTEIN BIOMARKERS MARKET 2019-2027 ($ MILLION)
TABLE 14 EUROPE GLYCO BIOMARKERS MARKET 2019-2027 ($ MILLION)
TABLE 15 EUROPE CANCER BIOMARKER MARKET BY CANCER TYPE 2019-2027 ($ MILLION)
TABLE 16 EUROPE LUNG CANCER MARKET 2019-2027 ($ MILLION)
TABLE 17 EUROPE BREAST CANCER MARKET 2019-2027 ($ MILLION)
TABLE 18 EUROPE COLORECTAL CANCER MARKET 2019-2027 ($ MILLION)
TABLE 19 EUROPE PROSTATE CANCER MARKET 2019-2027 ($ MILLION)
TABLE 20 EUROPE STOMACH CANCER MARKET 2019-2027 ($ MILLION)
TABLE 21 EUROPE OTHERS CANCER TYPE MARKET 2019-2027 ($ MILLION)
TABLE 22 EUROPE CANCER BIOMARKER MARKET BY APPLICATION 2019-2027 ($ MILLION)
TABLE 23 EUROPE DIAGNOSTICS MARKET 2019-2027 ($ MILLION)
TABLE 24 EUROPE DRUG DISCOVERY AND DEVELOPMENT MARKET 2019-2027 ($ MILLION)
TABLE 25 EUROPE PROGNOSTICS MARKET 2019-2027 ($ MILLION)
TABLE 26 EUROPE RISK ASSESSMENT MARKET 2019-2027 ($ MILLION)
TABLE 27 EUROPE OTHER APPLICATION MARKET 2019-2027 ($ MILLION)
TABLE 28 PATENT PRODUCTS WITH THE EXPIRY DATE
TABLE 29 PATENT PUBLICATIONS RELATED TO BREAST CANCER 2017
TABLE 30 PATENT PUBLICATIONS RELATED TO PROSTATE CANCER 2017
TABLE 31 PATENT PUBLICATIONS RELATED TO LUNG CANCER 2017
TABLE 32 EUROPE CANCER BIOMARKER MARKET BY COUNTRY 2018-2026 ($ MILLION)

FIGURES LIST
FIGURE 1 EUROPE CANCER BIOMARKER MARKET 2019-2027 ($ MILLION)
FIGURE 2 PHARMACOGENOMIC BIOMARKERS INFORMATION IN DRUG LABELING
FIGURE 3 PERCENTAGE OF PATIENTS INEFFECTIVE FOR PARTICULAR DRUG (%)
FIGURE 4 EUROPE CANCER BIOMARKER MARKET SHARE BY PROFILING TECHNOLOGY 2018 & 2027 (%)
FIGURE 5 EUROPE CANCER BIOMARKER MARKET SHARE BY BIOMARKER 2018 & 2027 (%)
FIGURE 6 EUROPE CANCER BIOMARKER MARKET SHARE BY CANCER TYPE 2018 & 2027 (%)
FIGURE 7 EUROPE CANCER BIOMARKER MARKET SHARE BY CANCER TYPE 2018 & 2027 (%)
FIGURE 8 PORTER'S FIVE FORCE ANALYSIS
FIGURE 9 EUROPE CANCER BIOMARKER MARKET REGIONAL OUTLOOK 2018 & 2027 (%)
FIGURE 10 GERMANY CANCER BIOMARKER MARKET 2019-2027 ($ MILLION)
FIGURE 11 THE UNITED KINGDOM CANCER BIOMARKER MARKET 2019-2027 ($ MILLION)
FIGURE 12 FRANCE CANCER BIOMARKER MARKET 2019-2027 ($ MILLION)
FIGURE 13 ITALY CANCER BIOMARKER MARKET 2019-2027 ($ MILLION)
FIGURE 14 SPAIN CANCER BIOMARKER MARKET 2019-2027 ($ MILLION)
FIGURE 15 REST OF EUROPE CANCER BIOMARKER MARKET 2019-2027 ($ MILLION)
FIGURE 16 MARKET SHARE ANALYSIS OF KEY PLAYERS 2017 (%)
  • Global Biomarkers Market Growth (Status and Outlook) 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 94
    According to our LPI (LP Information) latest study, the global Biomarkers market size was valued at US$ 61570 million in 2023. With growing demand in downstream market, the Biomarkers is forecast to a readjusted size of US$ 165240 million by 2030 with a CAGR of 15.1% during review period. The research report highlights the growth potential of the global Biomarkers market. Biomarkers are expected to show stable growth in the future market. However, product differentiation, reducing costs,......
  • Global Biomarker (Medicine) Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 04-Jan-2024        Price: US 3380 Onwards        Pages: 114
    Market Overview of Global Biomarker (Medicine) market: According to our latest research, the global Biomarker (Medicine) market looks promising in the next 5 years. As of 2022, the global Biomarker (Medicine) market was estimated at USD 54332.95 million, and it's anticipated to reach USD 82760.29 million in 2028, with a CAGR of 7.27% during the forecast years. Biomarkers (short for biological markers) are biological measures of a biological state. By definition, a biomarker i......
  • Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Growth (Status and Outlook) 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 131
    According to our LPI (LP Information) latest study, the global Commercializing Biomarkers in Therapeutic and Diagnostic Applications market size was valued at US$ 20920 million in 2023. With growing demand in downstream market, the Commercializing Biomarkers in Therapeutic and Diagnostic Applications is forecast to a readjusted size of US$ 29400 million by 2030 with a CAGR of 5.0% during review period. The research report highlights the growth potential of the global Commercializing Biom......
  • Global Biomarkers Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 05-Dec-2023        Price: US 3380 Onwards        Pages: 100
    Market Overview of Global Biomarkers market: According to our latest research, the global Biomarkers market looks promising in the next 5 years. As of 2022, the global Biomarkers market was estimated at USD 76755.97 million, and it's anticipated to reach USD 184776.75 million in 2028, with a CAGR of 15.77% during the forecast years. This report covers a research time span from 2018 to 2028, and presents a deep and comprehensive analysis of the global Biomarkers market, with a......
  • Global Biomarker Technology Market Research Report 2023
    Published: 01-Dec-2023        Price: US 2900 Onwards        Pages: 86
    This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Biomarker Technology market with multiple angles, which provides sufficient supports to readers' strategy and decision making. By Company - Abbott Laboratories - Quanterix - Bio-Rad Laboratories - Epigenomics - Agilent Technologies - Johnson & Johnson - Qiagen - Roche Ho......
  • Global Renal Biomarkers Market Research Report 2023
    Published: 01-Dec-2023        Price: US 2900 Onwards        Pages: 99
    This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Renal Biomarkers market with multiple angles, which provides sufficient supports to readers' strategy and decision making. By Company - Abbott Diagnostics - F. Hoffmann-La Roche - Beckman Coulter - Siemens Healthcare Diagnostics - Thermo Fisher Scientific - Astute Medical - Bio......
  • Global Central Nervous System (CNS) Biomarkers Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 30-Nov-2023        Price: US 3380 Onwards        Pages: 114
    Market Overview of Global Central Nervous System (CNS) Biomarkers market: According to our latest research, the global Central Nervous System (CNS) Biomarkers market looks promising in the next 5 years. As of 2022, the global Central Nervous System (CNS) Biomarkers market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. An overview of the global market for central nervous system (CNS) biomarke......
  • Global Cancer Biomarker Market Research Report 2023
    Published: 13-Nov-2023        Price: US 2900 Onwards        Pages: 109
    This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Cancer Biomarker market with multiple angles, which provides sufficient supports to readers' strategy and decision making. By Company - Thermo Fisher Scientific - Bio-Rad Laboratories - Roche Diagnostics - Qiagen - Illumina - GE Healthcare - Agilent Technologies - Biomér......
  • Biomarker Collaboration and Licensing Deals 2016-2023
    Published: 01-Nov-2023        Price: US 3995 Onwards        Pages: 300
    Biomarker Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the biomarker deals entered into by the worlds leading biopharma companies. Fully revised and updated, the report provides details of biomarker deals from 2016 to 2023. The report provides a detailed understanding and analysis of how and why companies enter biomarker deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercializ......
    • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs